Sucroferric oxyhydroxide: A review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis

Drugs

Volumn 75, Issue 5, 2015, Pages 533-542

  Greig, Sarah L ^a   Plosker, Greg L ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DRUG COMBINATION; FERRIC ION; PHOSPHATE; SUCROFERRIC OXYHYDROXIDE; SUCROSE;

ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG COMBINATION; DRUG INTERACTION; HUMAN; HYPERPHOSPHATEMIA; METABOLISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

CHELATING AGENTS; DRUG COMBINATIONS; DRUG INTERACTIONS; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; PHOSPHATES; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SUCROSE;

EID: 84937511565     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0366-1     Document Type: Article

References (29)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-130.
2. Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol. 2013;14:153.
3. Ketteler M, Wuthrich RP, Floege J. Management of hyperphosphataemia in chronic kidney disease-challenges and solutions. Clin Kidney J. 2013;6(2):128-36.
4. Cupisti A, Gallieni M, Rizzo MA, et al. Phosphate control in dialysis. Int J Nephrol Renovasc Dis. 2013;6:193-205.
5. National Institute for Health and Care Excellence. Hyperphosphataemia in chronic kidney disease: management of hyperphosphataemia in patients with stage 4 or 5 chronic kidney disease (NICE clinical guideline 157). 2013. http://www.nice.org.uk. Accessed 23 Feb 2015.
6. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1(4):697-703.
7. Fresenius Medical Care North America. Velphoro (sucroferric oxyhydroxide) chewable tablet for oral use: US prescribing information. 2014. http://www.velphoro.us. Accessed 23 Feb 2015.
8. Vifor Fresenius Medical Care Renal Pharma France. Velphoro 500 mg chewable tablets: EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 23 Feb 2015.
9. Kissei Pharmaceutical Co. Ltd. New drug application submitted for "PA21 (development code)" for treatment of hyperphosphatemia [media release]. 19 Nov 2014. http://kissei.co.jp/e-contents.
10. Wilhelm M, Gaillard S, Rakov V, et al. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;81(04):251-8.
11. Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant. 1999;14(4):863-7.
12. Lanz M, Baldischweiler J, Kriwet B, et al. Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev Ind Pharm. 2014;40(12):1623-31.
13. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010;74(1):4-11.
14. Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638-47.
15. Floege J, Covic AC, Ketteler M, et al. Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015. doi: 10.1093/ndt/gfv006.
16. Sprague SM, Covic A, Floege J, et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract plus poster]. In: National Kidney Foundation 2014 Spring Clinical Meeting. 2014.
17. Chong E, Kalia V, Willsie S, et al. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. J Nephrol. 2014;27(6):659-66.
18. Levesque V, Chong EMF, Moneuse P. Post-hoc analysis of pharmacodynamic interaction of PA21 with statins in a phase 3 study of PA21 in dialysis patients with hyperphosphatemia [abstract no. SA-PO568]. In: American Society of Nephrology Kidney Week 2013. 2013.
19. Floege J, Botha J, Chong E, et al. PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract no. SP257]. Nephrol Dial Transplant. 2014;29(Suppl 3):iii157.
20. Wuthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(2):280-9.
21. Vifor Inc. A phase 3 study to investigate the safety and efficacy of PA21, a phosphate binder, in dialysis patients [ClinicalTrials.gov identifier NCT01324128]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/. Accessed 23 Feb 2015.
22. Covic AC, Floege J, Ketteler M, et al. Efficacy and safety of PA21, a novel iron-based phosphate binder in CKD patients on peritoneal- and hemodialysis [abstract]. In: 15th Congress of the International Society of Peritoneal Dialysis. 2014.
23. Floege J. Efficacy and safety of the novel iron-based phosphate binder PA21 in peritoneal- and hemodialysis-dependent CKD patients [abstract plus poster]. In: 11th European Peritoneal Dialysis Meeting. 2013.
24. Covic A, Ketteler M, Rastogi A, et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract no. SP245]. Nephrol Dial Transplant. 2014;29(Suppl 3):iii153.
25. Malberti F. Hyperphosphataemia: treatment options. Drugs. 2013;73(7):673-88.
26. Nastou D, Fernandez-Fernandez B, Elewa U, et al. Next-generation phosphate binders: focus on iron-based binders. Drugs. 2014;74(8):863-77.
27. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-96.
28. Wang S, Alfieri T, Ramakrishnan K, et al. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(11):2092-9.
29. Gutzwiller FS, Braunhofer PG, Szucs TD, et al. Health economic evaluation of non-calcium-based phosphate binders in Scotland [abstract no. SP596]. Nephrol Dial Transplant. 2014;29(Suppl 3):iii271.